Steroid-dependent polyarthritis induced by immune checkpoint inhibitor therapy successfully treated with bimekizumab.

IF 2.7 4区医学 Q3 IMMUNOLOGY

Immunotherapy Pub Date : 2024-03-01 Epub Date: 2024-01-24 DOI:10.2217/imt-2023-0252

Robin Springer, Kristin Lange, Bernhard Homey, Stephan Meller, Harm-Henning Lindhof

引用次数: 0

Abstract

Immune checkpoint inhibitors (ICIs) are an integral part of modern-day cancer therapy. Along with a greatly improved antitumor response come a number of immune-related adverse events (irAEs), musculoskeletal irAEs rank among the less frequent manifestations. The mechanisms behind these events are poorly understood, and so far clear guidelines for therapeutic management beyond treatment with glucocorticosteroids are lacking. We present the case of a 72-year-old patient who developed a severe ICI-induced polyarthritis that could not be controlled by glucocorticosteroids. We initiated an immunomodulating therapy with the IL-17A/F/AF-inhibitor bimekizumab, which lead to a full clinical and sonographic remission.

查看原文本刊更多论文

免疫检查点抑制剂疗法诱发的类固醇依赖性多关节炎成功治愈了bimekizumab。

免疫检查点抑制剂（ICIs）是现代癌症治疗不可或缺的一部分。随着抗肿瘤反应的大幅改善，一些免疫相关不良事件（irAEs）也随之而来，其中肌肉骨骼irAEs是较少见的表现之一。人们对这些不良事件背后的机制知之甚少，迄今为止，除糖皮质激素治疗外，尚缺乏明确的治疗管理指南。我们介绍了一例 72 岁患者的病例，该患者出现了严重的 ICI 引起的多关节炎，糖皮质激素无法控制病情。我们开始使用 IL-17A/F/AF 抑制剂 bimekizumab 进行免疫调节治疗，结果临床症状和声像图完全缓解。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Immunotherapy 医学-免疫学

CiteScore

5.00

自引率

3.60%

发文量

113

审稿时长

6-12 weeks

期刊介绍： Many aspects of the immune system and mechanisms of immunomodulatory therapies remain to be elucidated in order to exploit fully the emerging opportunities. Those involved in the research and clinical applications of immunotherapy are challenged by the huge and intricate volumes of knowledge arising from this fast-evolving field. The journal Immunotherapy offers the scientific community an interdisciplinary forum, providing them with information on the most recent advances of various aspects of immunotherapies, in a concise format to aid navigation of this complex field. Immunotherapy delivers essential information in concise, at-a-glance article formats. Key advances in the field are reported and analyzed by international experts, providing an authoritative but accessible forum for this vitally important area of research. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal''s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.